Showing results (11-20 of 185) with videos related to
Sort By:
Pageof 19
Journal of Personalized Medicine|September 5, 2017
Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health EconomicsLouis P Garrison, Adrian TowseBritish Journal of Clinical Pharmacology|November 18, 2003
No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteersLynn Purkins, Nolan Wood, Diane Kleinermans, et al.Expert Review of Pharmacoeconomics & Outcomes Research|March 1, 2021
The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancerBoshen Jiao, Louis P GarrisonJournal of Managed Care & Specialty Pharmacy|September 27, 2019
A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and Precision MedicineLouis P Garrison, Adrian TowsePharmacoeconomics|January 21, 2010
Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical productsAdrian Towse, Louis P GarrisonValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 17, 2013
Economic incentives for evidence generation: promoting an efficient path to personalized medicineAdrian Towse, Louis P GarrisonBritish Journal of Clinical Pharmacology|November 18, 2003
Effect of food on the pharmacokinetics of multiple-dose oral voriconazoleLynn Purkins, Nolan Wood, Diane Kleinermans, et al.Health Affairs (Project Hope)|March 9, 2006
Implications of Part D for mentally ill dual eligibles: a challenge for MedicareNancy E Morden, Louis P GarrisonExpert Review of Pharmacoeconomics & Outcomes Research|April 14, 2010
Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancerJennie H Best, Louis P GarrisonValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 24, 2009
The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancerLouis P Garrison, David L VeenstraPageof 19